133
Participants
Start Date
December 22, 2021
Primary Completion Date
June 30, 2024
Study Completion Date
December 31, 2024
TJ107 +Pembrolizumab
TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
The First Affiliated Hospital of Anhui Medical University, Hefei
The Second Hospital of Anhui Medical University, Hefei
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Hainan General Hospital, Haikou
Harbin Medical University Cancer Hospital, Harbin
Hubei Cancer Hospital, Wuhan
Tongji Hospital, Tongji Medical College of Huzhong University of Science and Technology, Wuhan
The Second Xiangya Hospital of Central South University, Changsha
Jilin Cancer Hospital, Changchun
Jilin Guowen Hospital, Changchun
The First Hospital of Jilin University, Changchun
Yanbian University Hospital, Yanji
The First Hospital of China Medical University, Shenyang
Fudan University Shanghai Cancer Center, Shanghai
Shanghai East Hospital, Shanghai
Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine, Shanghai
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
TJ Biopharma Co., Ltd.
INDUSTRY